Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CG | P48736 | 19/20 | 0.83 |
| ▸ | PIK3C2A | O00443 | 2/20 | 0.62 |
| ▸ | PIK3C2B | O00750 | 2/20 | 0.62 |
| ▸ | PIK3CA | P42336 | 2/20 | 0.62 |
| ▸ | PRKDC | P78527 | 2/20 | 0.62 |
| ▸ | PIK3R1 | P27986 | 1/20 | 0.62 |
| ▸ | PIK3C3 | Q8NEB9 | 1/20 | 0.62 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.62 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2877647 | 1.00 | PIK3CG (0.83) | PIK3CGPIK3C2APIK3C2BPIK3CAPRKDC | |
| SCHEMBL5343611 | 0.91 | PIK3CG (0.70) | PIK3CGPIK3C2APIK3C2BPIK3CAPRKDC | |
| SCHEMBL5343609 | 0.91 | PIK3CG (0.70) | PIK3CGPIK3C2APIK3C2BPIK3CAPRKDC | |
| SCHEMBL5335927 | 0.91 | PIK3CG (1.00) | PIK3CGPIK3C2APIK3C2BPIK3CAPRKDC | |
| SCHEMBL5335930 | 0.91 | PIK3CG (1.00) | PIK3CGPIK3C2APIK3C2BPIK3CAPRKDC | |
| SCHEMBL5343844 | 0.90 | PIK3CG (0.68) | PIK3CGPIK3C2APIK3C2BPIK3CAPRKDC | |
| SCHEMBL5343840 | 0.90 | PIK3CG (0.68) | PIK3CGPIK3C2APIK3C2BPIK3CAPRKDC | |
| SCHEMBL5335850 | 0.88 | PIK3CG (0.71) | PIK3CGPIK3C2APIK3C2BPIK3CAPRKDC | |
| SCHEMBL5343532 | 0.88 | PIK3CG (0.67) | PIK3CGPIK3C2APIK3C2BPIK3CAPRKDC | |
| SCHEMBL5343531 | 0.88 | PIK3CG (0.67) | PIK3CGPIK3C2APIK3C2BPIK3CAPRKDC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7846925-B2 | Azolidinone-vinyl fused-benzene derivatives | MERCK SERONO SA (CH) | 2010-12-07 | — | — | US | disclosed |
| US-7846925-B2 | Azolidinone-vinyl fused-benzene derivatives | MERCK SERONO SA (CH) | 2010-12-07 | — | — | US | disclosed |
| US-20090306069-A1 | AZOLIDINONE-VINYL FUSED-BENZENE DERIVATIVES | LABORATOIRES SERONO S.A. (CH) | 2009-12-10 | — | — | US | disclosed |
| US-20090306069-A1 | AZOLIDINONE-VINYL FUSED-BENZENE DERIVATIVES | LABORATOIRES SERONO S.A. (CH) | 2009-12-10 | — | — | US | disclosed |
| US-7205295-B2 | Benzoxazin-3-ones and derivatives thereof as therapeutic agents | WARNER-LAMBERT COMPANY LLC (US) | 2007-04-17 | — | — | US | disclosed |
| US-20040121996-A1 | Benzoxazin-3-ones and derivatives thereof as therapeutic agents | BARVIAN NICOLE (US) | 2004-06-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090306069-A1 | AZOLIDINONE-VINYL FUSED-BENZENE DERIVATIVES | ZAP70, BRCA1, ZYX | PIK3CG 1265/4885PIK3C2A 1376/4885PIK3C2B 944/4885 |
| US-20040121996-A1 | Benzoxazin-3-ones and derivatives thereof as therapeutic agents | XDH, HAX1, CYP4X1 | PIK3CG 4186/4885PIK3C2A 4721/4885PIK3C2B 4743/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.